Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Canada GLP-1 Receptor Agonist Market Analysis The GLP-1 receptor agonist market in Canada was valued at USD 4.35 billion in 2025, supported by increasing prevalence of obesity and type 2 diabetes, expanding access to innovative diabetes therapies, and growing emphasis on chronic disease management
Many online programs operate on automatic subscriptions where medication is processed and shipped on a recurring basis with little to no individualized follow-up
Some patients prefer evening or bedtime administration, while others prefer morning
Share your specific health goals and ask for recommendations based on those goals
The scientific literature examining GLP-1 receptor agonists and colorectal cancer risk presents a complex and evolving picture
Some studies confirm that initiation of GLP-1 receptor agonists is associated with a lower risk of albuminuria progression and a less steep decline in eGFR compared to basal insulin or DPP-4 inhibitors, with hazard ratios for new macroalbuminuria events ranging from 0.80 to 0.89 [142]
